Overcoming MET-mediated resistance in oncogene-driven NSCLC

Nadine Reischmann, Carolin Schmelas, Miguel Ángel Molina‐Vila, Núria Jordana-Ariza, Daniel Kuntze, Silvia García-Román, Manon A. Simard, Doreen Musch, Christina Esdar, Joachim Albers,

iScience · 2023 · 10 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

This study evaluates the efficacy of combining targeted therapies with MET or SHP2 inhibitors to overcome MET-mediated resistance in different NSCLC subtypes. A prevalence study was conducted for MET amplification and overexpression in samples from patients with NSCLC who relapsed on ALK, ROS1, or RET tyrosine kinase inhibitors. MET-mediated resistance was detected in 37.5% of tissue biopsies, which allow the detection of MET overexpression, compared to 7.4% of liquid biopsies. The development of drug resistance by MET overexpression was confirmed in EGFR ex19del -, KRAS G12C -, HER2 ex20ins -, and TPM3-NTRK1 -mutant cell lines. The combination of targeted therapy with MET or SHP2 inhibitors was found to overcome MET-mediated resistance in both in vitro and in vivo assays. This study highlights the importance of considering MET overexpression as a resistance driver to NSCLC targeted therapies to better identify patients who could potentially benefit from combination approaches with MET or SHP2 inhibitors.

References

39